Cytokine disturbances in systemic lupus erythematosus

Arthritis Research and Therapy

Volumn 13, Issue 4, 2011, Pages

  Jacob, Noam ^a   Stohl, William ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

A 623; ALPHA INTERFERON; ALPHA INTERFERON RECEPTOR; ATACICEPT; AZATHIOPRINE; B CELL ACTIVATING FACTOR; BELIMUMAB; CORTICOSTEROID; CYCLOSPORIN; CYTOKINE; CYTOKINE RECEPTOR ANTAGONIST; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RONTALIZUMAB; SIFALIMUMAB; TABALUMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

CYTOKINE RELEASE; DRUG BINDING; DRUG DOSE INCREASE; DRUG EFFICACY; GLOMERULONEPHRITIS; HUMAN; NEPHRITIS; NEUTROPENIA; NONHUMAN; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SYSTEMIC LUPUS ERYTHEMATOSUS; ANIMAL; CLINICAL TRIAL (TOPIC); DRUG ANTAGONISM; IMMUNOLOGY; MOUSE; PATHOLOGY;

ANIMALS; B-CELL ACTIVATING FACTOR; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; CYTOKINES; HUMANS; INTERFERON-ALPHA; INTERLEUKIN-6; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80052201839     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3349     Document Type: Review

References (125)

1. Naka T, Nishimoto N, Kishimoto T. The paradigm of IL-6: from basic science to medicine. Arthritis Res 2002, 4(Suppl 3):S233-S242. 10.1186/ar565, 12110143.
2. Cash H, Relle M, Menke J, Brochhausen C, Jones SA, Topley N, Galle PR, Schwarting A. Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus. J Rheumatol 2010, 37:60-70. 10.3899/jrheum.090194, 19955044.
3. Schiffer L, Bethunaickan R, Ramanujam M, Huang W, Schiffer M, Tao H, Madaio MP, Bottinger EP, Davidson A. Activated renal macrophages are markers of disease onset and disease remission in lupus nephritis. J Immunol 2008, 180:1938-1947. 2587994, 18209092.
4. Alarcón-Riquelme ME, Möller G, Fernández C. Age-dependent responsiveness to interleukin-6 in B lymphocytes from a systemic lupus erythematosus-prone (NZB × NZW)F1 hybrid. Clin Immunol Immunopathol 1992, 62:264-269. 10.1016/0090-1229(92)90101-S, 1541052.
5. Mihara M, Fukui H, Koishihara Y, Saito M, Ohsugi Y. Immunologic abnormality in NZB/W F1 mice. Thymus-independent expansion of B cells responding to interleukin-6. Clin Exp Immunol 1990, 82:533-537. 1535487, 2265491.
6. Alarcón-Riquelme ME, Möller G, Fernández C. Macrophage depletion decreases IgG anti-DNA in cultures from (NZB × NZW)F1 spleen cells by eliminating the main source of IL-6. Clin Exp Immunol 1993, 91:220-225. 1554691, 8428389.
7. Ryffel B, Car BD, Gunn H, Roman D, Hiestand P, Mihatsch MJ. Interleukin-6 exacerbates glomerulonephritis in (NZB × NZW)F1 mice. Am J Pathol 1994, 144:927-937. 1887352, 8178944.
8. Finck BK, Chan B, Wofsy D. Interleukin 6 promotes murine lupus in NZB/NZW F1 mice. J Clin Invest 1994, 94:585-591. 10.1172/JCI117373, 296134, 8040314.
9. Mihara M, Takagi N, Takeda Y, Ohsugi Y. IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/W F1 mice. Clin Exp Immunol 1998, 112:397-402. 10.1046/j.1365-2249.1998.00612.x, 1904997, 9649207.
10. Richards HB, Satoh M, Shaw M, Libert C, Poli V, Reeves WH. Interleukin 6 dependence of anti-DNA antibody production: evidence for two pathways of autoantibody formation in pristane-induced lupus. J Exp Med 1998, 188:985-990. 10.1084/jem.188.5.985, 2213386, 9730900.
11. Pflegerl P, Vesely P, Hantusch B, Schlederer M, Zenz R, Janig E, Steiner G, Meixner A, Petzelbauer P, Wolf P, Soleiman A, Egger G, Moriggl R, Kishimoto T, Wagner EF, Kenner L. Epidermal loss of JunB leads to a SLE phenotype due to hyper IL-6 signaling. Proc Natl Acad Sci USA 2009, 106:20423-20428. 10.1073/pnas.0910371106, 2787143, 19918056.
12. Gröndal G, Gunnarsson I, Rönnelid J, Rogberg S, Klareskog L, Lundberg I. Cytokine production, serum levels and disease activity in systemic lupus erythematosus. Clin Exp Rheumatol 2000, 18:565-570.
13. Linker-Israeli M, Deans RJ, Wallace DJ, Prehn J, Ozeri-Chen T, Klinenberg JR. Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis. J Immunol 1991, 147:117-123.
14. Peterson E, Robertson AD, Emlen W. Serum and urinary interleukin-6 in systemic lupus erythematosus. Lupus 1996, 5:571-575. 10.1177/096120339600500603, 9116699.
15. Hagiwara E, Gourley MF, Lee S, Klinman DK. Disease severity in patients with systemic lupus erythematosus correlates with an increased ratio of interleukin-10:interferon-gamma-secreting cells in the peripheral blood. Arthritis Rheum 1996, 39:379-385. 10.1002/art.1780390305, 8607886.
16. Esposito P, Balletta MM, Procino A, Postiglione L, Memoli B. Interleukin-6 release from peripheral mononuclear cells is associated to disease activity and treatment response in patients with lupus nephritis. Lupus 2009, 18:1329-1330. 10.1177/0961203309106183, 19850661.
17. Kitani A, Hara M, Hirose T, Norioka K, Harigai M, Hirose W, Suzuki K, Kawakami M, Kawagoe M, Nakamura H. Heterogeneity of B cell responsiveness to interleukin 4, interleukin 6 and low molecular weight B cell growth factor in discrete stages of B cell activation in patients with systemic lupus erythematosus. Clin Exp Immunol 1989, 77:31-36. 1541934, 2788539.
18. Nagafuchi H, Suzuki N, Mizushima Y, Sakane T. Constitutive expression of IL-6 receptors and their role in the excessive B cell function in patients with systemic lupus erythematosus. J Immunol 1993, 151:6525-6534.
19. Takeno M, Nagafuchi H, Kaneko S, Wakisaka S, Oneda K, Takeba Y, Yamashita N, Suzuki N, Kaneoka H, Sakane T. Autoreactive T cell clones from patients with systemic lupus erythematosus support polyclonal autoantibody production. J Immunol 1997, 15:3529-3538.
20. Hirohata S, Kanai Y, Mitsuo A, Tokano Y, Hashimoto H, . NPSLE Research Subcommittee Accuracy of cerebrospinal fluid IL-6 testing for diagnosis of lupus psychosis. A multicenter retrospective study. Clin Rheumatol 2009, 28:1319-1323. 10.1007/s10067-009-1226-8, 19593599, NPSLE Research Subcommittee.
21. Iwano M, Dohi K, Hirata E, Kurumatani N, Horii Y, Shiiki H, Fukatsu A, Matsuda T, Hirano T, Kishimoto T. Urinary levels of IL-6 in patients with active lupus nephritis. Clin Nephrol 1993, 40:16-21.
22. Herrera-Esparza R, Barbosa-Cisneros O, Villalobos-Hurtado R, Avalos-Díaz E. Renal expression of IL-6 and TNFα genes in lupus nephritis. Lupus 1998, 7:154-158. 10.1191/096120398678919949, 9607638.
23. Malide D, Russo P, Bendayan M. Presence of tumor necrosis factor alpha and interleukin-6 in renal mesangial cells of lupus nephritis patients. Hum Pathol 1995, 26:558-564. 10.1016/0046-8177(95)90253-8, 7750940.
24. Illei GG, Shirota Y, Yarboro CH, Daruwalla J, Tackey E, Takada K, Fleisher T, Balow JE, Lipsky PE. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum 2010, 62:542-552. 10.1002/art.27221, 3057537, 20112381.
25. MacEwan DJ. TNF ligands and receptors - a matter of life and death. Br J Pharmacol 2002, 135:855-875. 10.1038/sj.bjp.0704549, 1573213, 11861313.
26. McDevitt H, Munson S, Ettinger R, Wu A. Multiple roles for tumor necrosis factor-alpha and lymphotoxin alpha/beta in immunity and autoimmunity. Arthritis Res 2002, 4(Suppl 3):S141-S152. 10.1186/ar570, 12110133.
27. Boswell JM, Yui MA, Burt DW, Kelley VE. Increased tumor necrosis factor and IL-1 beta gene expression in the kidneys of mice with lupus nephritis. J Immunol 1988, 141:3050-3054.
28. Yokoyama H, Kreft B, Kelley VR. Biphasic increase in circulating and renal TNF-α in MRL-lpr mice with differing regulatory mechanisms. Kidney Int 1995, 47:122-130. 10.1038/ki.1995.14, 7731137.
29. Edwards CK, Zhou T, Zhang J, Baker TJ, De M, Long RE, Borcherding DR, Bowlin TL, Bluethmann H, Mountz JD. Inhibition of superantigen-induced proinflammatory cytokine production and inflammatory arthritis in MRL-lpr/lpr mice by a transcriptional inhibitor of TNF-α. J Immunol 1996, 157:1758-1772.
30. Segal R, Dayan M, Zinger H, Mozes E. Suppression of experimental systemic lupus erythematosus (SLE) in mice via TNF inhibition by an anti-TNFα monoclonal antibody and by pentoxiphylline. Lupus 2001, 10:23-31. 10.1191/096120301675275538, 11243506.
31. Jacob CO, McDevitt HO. Tumour necrosis factor-alpha in murine autoimmune 'lupus' nephritis. Nature 1988, 331:356-358. 10.1038/331356a0, 2893286.
32. Gordon C, Ranges GE, Greenspan JS, Wofsy D. Chronic therapy with recombinant tumor necrosis factor-alpha in autoimmune NZB/NZW F1 mice. Clin Immunol Immunopathol 1989, 52:421-434. 10.1016/0090-1229(89)90157-8, 2758698.
33. Gordon C, Wofsy D. Effects of recombinant murine tumor necrosis factor-alpha on immune function. J Immunol 1990, 144:1753-1758.
34. Kontoyiannis D, Kollias G. Accelerated autoimmunity and lupus nephritis in NZB mice with an engineered heterozygous deficiency in tumor necrosis factor. Eur J Immunol 2000, 30:2038-2047. 10.1002/1521-4141(200007)30:7<2038::AID-IMMU2038>3.0.CO;2-K, 10940893.
35. Kollias G, Kontoyianni D. Role of TNF/TNFR in autoimmunity: specific TNF receptor blockade may be advantageous to anti-TNF treatments. Cytokine Growth Factor Rev 2002, 13:315-321. 10.1016/S1359-6101(02)00019-9, 12220546.
36. Vielhauer V, Mayadas TN. Functions of TNF and its receptors in renal disease: distinct roles in inflammatory tissue injury and immune regulation. Semin Nephrol 2007, 27:286-308. 10.1016/j.semnephrol.2007.02.004, 17533007.
37. Vielhauer V, Stavrakis G, Mayadas TN. Renal cell-expressed TNF receptor 2, not receptor 1, is essential for the development of glomerulonephritis. J Clin Invest 2005, 115:1199-1209. 1070636, 15841213.
38. Zhou T, Edwards CK, Yang P, Wang Z, Bluethmann H, Mountz JD. Greatly accelerated lymphadenopathy and autoimmune disease in lpr mice lacking tumor necrosis factor receptor I. J Immunol 1996, 156:2661-2665.
39. Jacob N, Yang H, Pricop L, Liu Y, Gao X, Zheng SG, Wang J, Gao HX, Putterman C, Koss MN, Stohl W, Jacob CO. Accelerated pathological and clinical nephritis in systemic lupus erythematosus-prone New Zealand Mixed 2328 mice doubly deficient in TNF receptor 1 and TNF receptor 2 via a Th17-associated pathway. J Immunol 2009, 182:2532-2541. 10.4049/jimmunol.0802948, 2790862, 19201910.
40. Studnicka-Benke A, Steiner G, Petera P, Smolen JS. Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. Br J Rheumatol 1996, 35:1067-1074. 10.1093/rheumatology/35.11.1067, 8948291.
41. Gabay C, Cakir N, Moral F, Roux-Lombard P, Meyer O, Dayer JM, Vischer T, Yazici H, Guerne PA. Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity. J Rheumatol 1997, 24:303-308.
42. Zhu LJ, Landolt-Marticorena C, Li T, Yang X, Yu XQ, Gladman DD, Urowitz MB, Fortin PR, Wither JE. Altered expression of TNF-α signaling pathway proteins in systemic lupus erythematosus. J Rheumatol 2010, 37:1658-1666. 10.3899/jrheum.091123, 20516030.
43. Gómez D, Correa PA, Gómez LM, Cadena J, Molina JF, Anaya JM. Th1/Th2 cytokines in patients with systemic lupus erythematosus: is tumor necrosis factor alpha protective?. Semin Arthritis Rheum 2004, 33:404-413. 10.1016/j.semarthrit.2003.11.002, 15190525.
44. Jacob CO, Fronek Z, Lewis GD, Koo M, Hansen JA, McDevitt HO. Heritable major histocompatibility complex class II-associated differences in production of tumor necrosis factor alpha: relevance to genetic predisposition to systemic lupus erythematosus. Proc Natl Acad Sci USA 1990, 87:1233-1237. 10.1073/pnas.87.3.1233, 53445, 2105500.
45. Zhu L, Yang X, Chen W, Li X, Ji Y, Mao H, Nie J, Yu X. Decreased expressions of the TNF-α signaling adapters in peripheral blood mononuclear cells (PBMCs) are correlated with disease activity in patients with systemic lupus erythematosus. Clin Rheumatol 2007, 26:1481-1489. 10.1007/s10067-006-0531-8, 17235653.
46. Zhu L, Yang X, Ji Y, Chen W, Guan W, Zhou SF, Yu X. Up-regulated renal expression of TNF-α signaling adapter proteins in lupus glomerulonephritis. Lupus 2009, 18:116-127. 10.1177/0961203308094764, 19151112.
47. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, Leeb B, Breedveld FC, Macfarlane JD, Bijl H. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994, 344:1105-1110. 10.1016/S0140-6736(94)90628-9, 7934491.
48. Lenercept Multiple Sclerosis Study Group; University of British Columbia MS/MRI Analysis Group TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 1999, 53:457-465. Lenercept Multiple Sclerosis Study Group; University of British Columbia MS/MRI Analysis Group.
49. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996, 14:397-440. 10.1146/annurev.immunol.14.1.397, 8717520.
50. Sicotte NL, Voskuhl RR. Onset of multiple sclerosis associated with anti-TNF therapy. Neurology 2001, 57:1885-1888.
51. Sandborn WJ, Hanauer SB. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis 1999, 5:119-133.
52. Soforo E, Baumgartner M, Francis L, Allam F, Phillips PE, Perl A. Induction of systemic lupus erythematosus with tumor necrosis factor blockers. J Rheumatol 2010, 37:204-205. 10.3899/jrheum.081312, 20040644.
53. Aringer M, Graninger WB, Steiner G, Smolen JS. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an openlabel study. Arthritis Rheum 2004, 50:3161-3169. 10.1002/art.20576, 15476222.
54. Matsumura R, Umemiya K, Sugiyama T, Sueishi M, Umibe T, Ichikawa K, Yoshimura M. Anti-tumor necrosis factor therapy in patients with difficult-to-treat lupus nephritis: a prospective series of nine patients. Clin Exp Rheumatol 2009, 27:416-421.
55. Aringer M, Houssiau F, Gordon C, Graninger WB, Voll RE, Rath E, Steiner G, Smolen JS. Adverse events and efficacy of TNF-α blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients. Rheumatology (Oxford) 2009, 48:1451-1454.
56. Baccala R, Hoebe K, Kono DH, Beutler B, Theofilopoulos AN. TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity. Nat Med 2007, 13:543-551. 10.1038/nm1590, 17479100.
57. Santiago-Raber M-L, Baccala R, Haraldsson KM, Choubey D, Stewart TA, Kono DH, Theofilopoulos AN. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J Exp Med 2003, 197:777-788. 10.1084/jem.20021996, 2193854, 12642605.
58. Agrawal H, Jacob N, Carreras E, Bajana S, Putterman C, Turner S, Neas B, Mathian A, Koss MN, Stohl W, Kovats S, Jacob CO. Deficiency of type I IFN receptor in lupus-prone New Zealand mixed 2328 mice decreases dendritic cell numbers and activation and protects from disease. J Immunol 2009, 183:6021-6029. 10.4049/jimmunol.0803872, 2766036, 19812195.
59. Mathian A, Weinberg A, Gallegos M, Banchereau J, Koutouzov S. IFN-α induces early lethal lupus in preautoimmune (New Zealand Black × New Zealand White) F1 but not in BALB/c mice. J Immunol 2005, 174:2499-2506.
60. Fairhurst AM, Mathian A, Connolly JE, Wang A, Gray HF, George TA, Boudreaux CD, Zhou XJ, Li QZ, Koutouzov S, Banchereau J, Wakeland EK. Systemic IFN-α drives kidney nephritis in B6.Sle123 mice. Eur J Immunol 2008, 38:1948-1960. 10.1002/eji.200837925, 2699327, 18506882.
61. Ramanujam M, Kahn P, Huang W, Tao H, Madaio MP, Factor SM, Davidson A. Interferon-alpha treatment of female (NZW × BXSB)F(1) mice mimics some but not all features associated with the Yaa mutation. Arthritis Rheum 2009, 60:1096-1101. 10.1002/art.24414, 2703814, 19333924.
62. Mathian A, Gallegos M, Pascual V, Banchereau J, Koutouzov S. Interferon-α induces unabated production of short-lived plasma cells in preautoimmune lupus-prone (NZB × NZW)F1 mice but not in BALB/c mice. Eur J Immunol 2011, 41:863-872. 10.1002/eji.201040649, 21312191.
63. Hron JD, Peng SL. Type I IFN protects against murine lupus. J Immunol 2004, 173:2134-2142.
64. Li J, Liu Y, Xie C, Zhu J, Kreska D, Morel L, Mohan C. Deficiency of type I interferon contributes to Sle2-associated component lupus phenotypes. Arthritis Rheum 2005, 52:3063-3072. 10.1002/art.21307, 16200585.
65. Nickerson KM, Christensen SR, Shupe J, Kashgarian M, Kim D, Elkon K, Shlomchik MJ. TLR9 regulates TLR7- and MyD88-dependent autoantibody production and disease in a murine model of lupus. J Immunol 2010, 184:1840-1848. 10.4049/jimmunol.0902592, 20089701.
66. Barrat FJ, Meeker T, Chan JH, Guiducci C, Coffmann RL. Treatment of lupusprone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Eur J Immunol 2007, 37:3582-3586. 10.1002/eji.200737815, 18034431.
67. Theofilopoulos AN, Baccala R, Beutler B, Kono DH. Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol 2005, 23:307-336. 10.1146/annurev.immunol.23.021704.115843, 15771573.
68. Niewold TB, Hua J, Lehman TJ, Harley JB, Crow MK. High serum IFN-α activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun 2007, 8:492-502. 10.1038/sj.gene.6364408, 2702174, 17581626.
69. Niewold TB, Adler JE, Glenn SB, Lehman TJ, Harley JB, Crow MK. Age- and sex-related patterns of serum interferon-alpha activity in lupus families. Arthritis Rheum 2008, 58:2113-2119. 10.1002/art.23619, 2729701, 18576315.
70. Kirou KA, Lee C, George S, Louca K, Peterson MG, Crow MK. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum 2005, 52:1491-1503. 10.1002/art.21031, 15880830.
71. Dall'era MC, Cardarelli PM, Preston BT, Witte A, Davis JC. Type I interferon correlates with serological and clinical manifestations of SLE. Ann Rheum Dis 2005, 64:1692-1697. 10.1136/ard.2004.033753, 1755300, 15843451.
72. Landolt-Marticorena C, Bonventi G, Lubovich A, Ferguson C, Unnithan T, Su J, Gladman DD, Urowitz M, Fortin PR, Wither J. Lack of association between the interferon-alpha signature and longitudinal changes in disease activity in systemic lupus erythematosus. Ann Rheum Dis 2009, 68:1440-1446. 10.1136/ard.2008.093146, 18772188.
73. Bauer JW, Baechler EC, Petri M, Batliwalla FM, Crawford D, Ortmann WA, Espe KJ, Li W, Patel DD, Gregersen PK, Behrens TW. Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med 2006, 3:e491. 10.1371/journal.pmed.0030491, 1702557, 17177599.
74. Fu Q, Chen X, Cui H, Guo Y, Chen J, Shen N, Bao C. Association of elevated transcript levels of interferon-inducible chemokines with disease activity and organ damage in systemic lupus erythematosus patients. Arthritis Res Ther 2008, 10:R112. 10.1186/ar2510, 2592795, 18793417.
75. Bauer JW, Petri M, Batliwalla FM, Koeuth T, Wilson J, Slattery C, Panoskaltsis-Mortari A, Gregersen PK, Behrens TW, Baechler EC. Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study. Arthritis Rheum 2009, 60:3098-3107. 10.1002/art.24803, 2842939, 19790071.
76. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, Shark KB, Grande WJ, Hughes KM, Kapur V, Gregersen PK, Behrens TW. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 2003, 100:2610-2615. 10.1073/pnas.0337679100, 151388, 12604793.
77. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, Pascual V. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003, 197:711-723. 10.1084/jem.20021553, 2193846, 12642603.
78. Peterson KS, Huang JF, Zhu J, D'Agati V, Liu X, Miller N, Erlander MG, Jackson MR, Winchester RJ. Characterization of heterogeneity in the molecular pathogenesis of lupus nephritis from transcriptional profiles of laser-captured glomeruli. J Clin Invest 2004, 113:1722-1733. 420500, 15199407.
79. Nzeusseu Toukap A, Galant C, Theate I, Maudoux AL, Lories RJ, Houssiau FA, Lauwerys BR. Identification of distinct gene expression profiles in the synovium of patients with systemic lupus erythematosus. Arthritis Rheum 2007, 56:1579-1588. 10.1002/art.22578, 17469140.
80. Tucci M, Quatraro C, Lombardi L, Pellegrino C, Dammacco F, Silvestris F. Glomerular accumulation of plasmacytoid dendritic cells in active lupus nephritis: role of interleukin-18. Arthritis Rheum 2008, 58:251-262. 10.1002/art.23186, 18163476.
81. Farkas L, Beiske K, Lund-Johansen F, Brandtzaeg P, Jahnsen FL. Plasmacytoid dendritic cells (natural interferon-alpha/beta-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am J Pathol 2001, 159:237-243. 10.1016/S0002-9440(10)61689-6, 1850412, 11438470.
82. Jego G, Palucka AK, Blanck JP, Chalouni C, Pascual V, Banchereau J. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 2003, 19:225-234. 10.1016/S1074-7613(03)00208-5, 12932356.
83. Le Bon A, Thompson C, Kamphuis E, Durand V, Rossmann C, Kalinke U, Tough DF. Cutting edge: enhancement of antibody responses through direct stimulation of B and T cells by type I IFN. J Immunol 2006, 176:2074-2078.
84. Ruuth K, Carlsson L, Hallberg B, Lundgren E. Interferon-alpha promotes survival of human primary B-lymphocytes via phosphatidylinositol 3-kinase. Biochem Biophys Res Commun 2001, 284:583-586. 10.1006/bbrc.2001.5025, 11396940.
85. Suen JL, Li HT, Jong YJ, Chiang BL, Yen JH. Altered homeostasis of CD4(+) FoxP3(+) regulatory T-cell subpopulations in systemic lupus erythematosus. Immunology 2009, 127:196-205. 10.1111/j.1365-2567.2008.02937.x, 2691785, 18800986.
86. Venigalla RK, Tretter T, Krienke S, Max R, Eckstein V, Blank N, Fiehn C, Ho AD, Lorenz HM. Reduced CD4+, CD25-T cell sensitivity to the suppressive function of CD4+, CD25high, CD127-/low regulatory T cells in patients with active systemic lupus erythematosus. Arthritis Rheum 2008, 58:2120-2130. 10.1002/art.23556, 18576316.
87. Yan B, Ye S, Chen G, Kuang M, Shen N, Chen S. Dysfunctional CD4+, CD25+ regulatory T cells in untreated active systemic lupus erythematosus secondary to interferon-alpha-producing antigen-presenting cells. Arthritis Rheum 2008, 58:801-812. 10.1002/art.23268, 18311820.
88. Rönnblom LE, Alm GV, Oberg KE. Possible induction of systemic lupus erythematosus by interferon-alpha treatment in a patient with a malignant carcinoid tumour. J Intern Med 1990, 227:207-210. 10.1111/j.1365-2796.1990.tb00144.x, 1690258.
89. Niewold TB, Swedler WI. Systemic lupus erythematosus arising during interferon-alpha therapy for cryoglobulinemic vasculitis associated with hepatitis C. Clin Rheumatol 2005, 24:178-181. 10.1007/s10067-004-1024-2, 15565395.
90. Niewold TB. Interferon alpha-induced lupus: proof of principle. J Clin Rheumatol 2008, 14:131-132. 10.1097/RHU.0b013e318177627d, 2743115, 18525429.
91. Sigurdsson S, Nordmark G, Göring HH, Lindroos K, Wiman AC, Sturfelt G, Jönsen A, Rantapää-Dahlqvist S, Möller B, Kere J, Koskenmies S, Widén E, Eloranta ML, Julkunen H, Kristjansdottir H, Steinsson K, Alm G, Rönnblom L, Syvänen AC. Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. Am J Hum Genet 2005, 76:528-537. 10.1086/428480, 1196404, 15657875.
92. Hellquist A, Järvinen TM, Koskenmies S, Zucchelli M, Orsmark-Pietras C, Berglind L, Panelius J, Hasan T, Julkunen H, D'Amato M, Saarialho-Kere U, Kere J. Evidence for genetic association and interaction between the TYK2 and IRF5 genes in systemic lupus erythematosus. J Rheumatol 2009, 36:1631-1638. 10.3899/jrheum.081160, 19567624.
93. Niewold TB, Kelly JA, Flesch MH, Espinoza LR, Harley JB, Crow MK. Association of the IRF5 risk haplotype with high serum interferon-alpha activity in systemic lupus erythematosus patients. Arthritis Rheum 2008, 58:2481-2487. 10.1002/art.23613, 2621107, 18668568.
94. Harley JB, Alarcón-Riquelme ME, Criswell LA, Jacob CO, Kimberly RP, Moser KL, Tsao BP, Vyse TJ, Langefeld CD, Nath SK, Guthridge JM, Cobb BL, Mirel DB, Marion MC, Williams AH, Divers J, Wang W, Frank SG, Namjou B, Gabriel SB, Lee AT, Gregersen PK, Behrens TW, Taylor KE, Fernando M, Zidovetzki R, Gaffney PM, Edberg JC, Rioux JD, Ojwang JO, et al. International Consortium for Systemic Lupus Erythematosus Genetics (SLEGEN) Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat Genet 2008, 40:204-210. 10.1038/ng.81, 18204446, International Consortium for Systemic Lupus Erythematosus Genetics (SLEGEN).
95. Kariuki SN, Kirou KA, MacDermott EJ, Barillas-Arias L, Crow MK, Niewold TB. Cutting edge: autoimmune disease risk variant of STAT4 confers increased sensitivity to IFN-alpha in lupus patients in vivo. J Immunol 2009, 182:34-38. 2716754, 19109131.
96. Taylor KE, Remmers EF, Lee AT, Ortmann WA, Plenge RM, Tian C, Chung SA, Nititham J, Hom G, Kao AH, Demirci FY, Kamboh MI, Petri M, Manzi S, Kastner DL, Seldin MF, Gregersen PK, Behrens TW, Criswell LA. Specificity of the STAT4 genetic association for severe disease manifestations of systemic lupus erythematosus. PLoS Genet 2008, 4:e1000084. 10.1371/journal.pgen.1000084, 2377340, 18516230.
97. Abelson AK, Delgado-Vega AM, Kozyrev SV, Sánchez E, Velázquez-Cruz R, Eriksson N, Wojcik J, Linga Reddy MV, Lima G, D'Alfonso S, Migliaresi S, Baca V, Orozco L, Witte T, Ortego-Centeno N, , Abderrahim H, Pons-Estel BA, Gutiérrez C, Suárez A, González-Escribano MF, Martin J, Alarcón-Riquelme ME. AADEA Group STAT4 associates with systemic lupus erythematosus through two independent effects that correlate with gene expression and act additively with IRF5 to increase risk. Ann Rheum Dis 2009, 68:1746-1753. 10.1136/ard.2008.097642, 19019891, AADEA Group.
98. Jacob CO, Zhu J, Armstrong DL, Yan M, Han J, Zhou XJ, Thomas JA, Reiff A, Myones BL, Ojwang JO, Kaufman KM, Klein-Gitelman M, McCurdy D, Wagner-Weiner L, Silverman E, Ziegler J, Kelly JA, Merrill JT, Harley JB, Ramsey-Goldman R, Vila LM, Bae SC, Vyse TJ, Gilkeson GS, Gaffney PM, Moser KL, Langefeld CD, Zidovetzki R, Mohan C. Identification of IRAK1 as a risk gene with critical role in the pathogenesis of systemic lupus erythematosus. Proc Natl Acad Sci USA 2009, 106:6256-6261. 10.1073/pnas.0901181106, 2669395, 19329491.
99. Denny MF, Thacker S, Mehta H, Somers EC, Dodick T, Barrat FJ, McCune WJ, Kaplan MJ. Interferon-α promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis. Blood 2007, 110:2907-2915. 10.1182/blood-2007-05-089086, 2018671, 17638846.
100. Lee PY, Li Y, Richards HB, Chan FS, Zhuang H, Narain S, Butfiloski EJ, Sobel ES, Reeves WH, Segal MS. Type I interferon as a novel risk factor for endothelial progenitor cell depletion and endothelial dysfunction in systemic lupus erythematosus. Arthritis Rheum 2007, 56:3759-3769. 10.1002/art.23035, 17968925.
101. Zhao W, Somers E, McCune WJ, Kaplan MJ. Type I interferon signatures are associated with vascular risk and atherosclerosis in systemic lupus erythematosus [abstract]. Arthritis Rheum 2009, 59:S582.
102. Yao Y, Richman L, Higgs BW, Morehouse CA, de los Reyes M, Brohawn P, Zhang J, White B, Coyle AJ, Kiener PA, Jallal B. Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum 2009, 60:1785-1796. 10.1002/art.24557, 19479852.
103. McBride JM, Wallace DJ, Yao Z, Morimoto A, Jiang J, Maciuca R, McLean I, Drappa J. Dose-dependent modulation of interferon regulated genes with administration of single and repeat doses of rontalizumab in a phase I, placebo controlled, double blind, dose escalation study in SLE. Arthritis Rheum 2009, 60(Suppl):S775-S776.
104. Mackay F, Schneider P. Cracking the BAFF code. Nat Rev Immunol 2009, 9:491-502. 10.1038/nri2572, 19521398.
105. Mackay F, Woodcock SA, Lawton P, Ambrose C, Baetscher M, Schneider P, Tschopp J, Browning JL. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999, 190:1697-1710. 10.1084/jem.190.11.1697, 2195729, 10587360.
106. Stohl W, Xu D, Kim KS, Koss MN, Jorgensen TN, Deocharan B, Metzger TE, Bixler SA, Hong YS, Ambrose CM, Mackay F, Morel L, Putterman C, Kotzin BL, Kalled SL. BAFF overexpression and accelerated glomerular disease in mice with an incomplete genetic predisposition to systemic lupus erythematosus. Arthritis Rheum 2005, 52:2080-2091. 10.1002/art.21138, 15986357.
107. Jacob CO, Pricop L, Putterman C, Koss MN, Liu Y, Kollaros M, Bixler SA, Ambrose CM, Scott ML, Stohl W. Paucity of clinical disease despite serological autoimmunity and kidney pathology in lupus-prone New Zealand mixed 2328 mice deficient in BAFF. J Immunol 2006, 177:2671-2680. 2896675, 16888029.
108. Ramanujam M, Bethunaickan R, Huang W, Tao H, Madaio MP, Davidson A. Selective blockade of BAFF for the prevention and treatment of systemic lupus erythematosus nephritis in NZM2410 mice. Arthritis Rheum 2010, 62:1457-1468. 2917190, 20131293.
109. Jacob N, Guo S, Mathian A, Koss MN, Gindea S, Putterman C, Jacob CO, Stohl W. B cell and BAFF dependence of IFN-α-exaggerated disease in systemic lupus erythematosus-prone NZM 2328 mice. J Immunol 2011, 186:4984-4993. 10.4049/jimmunol.1000466, 21383240.
110. Stohl W, Looney RJ. B cell depletion therapy in systemic rheumatic diseases: different strokes for different folks?. Clin Immunol 2006, 121:1-12. 10.1016/j.clim.2006.03.010, 16697258.
111. Collins CE, Gavin AL, Migone TS, Hilbert DM, Nemazee D, Stohl W. B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels. Arthritis Res Ther 2006, 8:R6. 10.1186/ar1855, 1526545, 16356193.
112. Chu VT, Enghard P, Schürer S, Steinhauser G, Rudolph B, Riemekasten G, Berek C. Systemic activation of the immune system induces aberrant BAFF and APRIL expression in B cells in patients with systemic lupus erythematosus. Arthritis Rheum 2009, 60:2083-2093. 10.1002/art.24628, 19565488.
113. Lee YH, Ota F, Kim-Howard X, Kaufman KM, Nath SK. APRIL polymorphism and systemic lupus erythematosus (SLE) susceptibility. Rheumatology (Oxford) 2007, 46:1274-1276.
114. Kawasaki A, Tsuchiya N, Fukazawa T, Hashimoto H, Tokunaga K. Analysis on the association of human BLYS (BAFF, TNFSF13B) polymorphisms with systemic lupus erythematosus and rheumatoid arthritis. Genes Immun 2002, 3:424-429. 10.1038/sj.gene.6363923, 12424625.
115. Baker KP, Edwards BM, Main SH, Choi GH, Wager RE, Halpern WG, Lappin PB, Riccobene T, Abramian D, Sekut L, Sturm B, Poortman C, Minter RR, Dobson CL, Williams E, Carmen S, Smith R, Roschke V, Hilbert DM, Vaughan TJ, Albert VR. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum 2003, 48:3253-3265. 10.1002/art.11299, 14613291.
116. Furie R, Stohl W, Ginzler EM, Becker M, Mishra N, Chatham W, Merrill JT, Weinstein A, McCune WJ, Zhong J, Cai W, Freimuth W, . Belimumab Study Group Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther 2008, 10:R109. 10.1186/ar2506, 2592791, 18786258, Belimumab Study Group.
117. Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT, Petri MA, Ginzler EM, Chatham WW, McCune WJ, Fernández V, Chevrier MR, Zhong ZJ, Freimuth WW. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 2009, 61:1168-1178. 10.1002/art.24699, 2758229, 19714604.
118. Furie RA, Petri MA, Wallace DJ, Ginzler EM, Merrill JT, Stohl W, Chatham WW, Strand V, Weinstein A, Chevrier MR, Zhong ZJ, Freimuth WW. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum 2009, 61:1143-1151. 10.1002/art.24698, 2748175, 19714615.
119. Navarra S, Guzman R, Gallacher A, Levy RA, Li EK, Thomas M, Jimenez R, Leon M, Hall S, Lan JL, Nasonov E, Tanasescu C, Kim HY, Pineda L, Zhong ZJ, Freimuth W, Petri MA, . BLISS-52 Study Group Belimumab, a BLyS-specific inhibitor, reduced disease activity, flares and prednisone use in patients with active SLE: efficacy and safety results from the phase 3 BLISS-52 study [abstract]. Arthritis Rheum 2009, 60:3859. BLISS-52 Study Group.
120. Furie R, Zamani O, Wallace D, Tegzová D, Petri M, Merrill JT, Chatham W, Stohl W, Schwarting A, Cooper S, Zhong ZJ, Freimuth W, Hough D, van Vollenhoven RF, . BLISS-76 Study Group Belimumab, a BLyS-specific inhibitor, reduced disease activity and severe flares in seropositive SLE patients: BLISS-76 study results through wk 76. Arthritis Rheum 2010, 62:S606. BLISS-76 Study Group.
121. Manzi S, Sanchez-Guerrero J, Merrill JT, Furie RA, Gladman D, Navarra S, Ginzler EM, D'Cruz D, Doria A, Cooper S, Zhong ZJ, Hough D, Freimuth W, Petri M, . BLISS-52 and BLISS-76 Study Groups Belimumab, a BLyS-specific inhibitor, reduced disease activity across multiple organ domains: combined efficacy results from the phase 3 BLISS-52 and -76 studies. Arthritis Rheum 2010, 62:S607. BLISS-52 and BLISS-76 Study Groups.
122. Dall'Era M, Chakravarty E, Wallace D, Genovese M, Weisman M, Kavanaugh A, Kalunian K, Dhar P, Vincent E, Pena-Rossi C, Wofsy D. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum 2007, 56:4142-4150. 10.1002/art.23047, 18050206.
123. Stohl W, Merrill JT, Looney RJ, Buyon J, Wallace DJ, Weisman M, Ginzler EM, Cooke B, Holloway D, Kuchimanchi K, Cheah TC, Rasmussen E, Ferbas J, Belouski SS, Zack DJ. Phase 1a single- and phase 1b multiple-dose studies of AMG 623 (an anti-BAFF peptibody) in systemic lupus erythematosus (SLE). Arthritis Rheum 2008, 58:S565.
124. Stohl W, Hiepe F, Thomas M, Scheinberg M, Clarke A, Aranow C, Jimenez R, Wellborne F, Abud-Mendoza C, Hough D, Pineda L, Migone TS, Freimuth W, Chatham W, . BLISS-52 and BLISS-76 Study Groups Belimumab, a BLyS-specific inhibitor, significantly reduced autoantibodies, normalized low complement, and reduced selected B-cell populations in patients with seropositive systemic lupus erythematosus (SLE): the phase 3 BLISS studies [abstract]. Arthritis Rheum 2010, 62:S480. BLISS-52 and BLISS-76 Study Groups.
125. Kikly K, Manetta J, Smith H, Wierda D, Witcher D. Characterization of LY2127399, a neutralizing antibody for BAFF [abstract]. Arthritis Rheum 2009, 60:693.